Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News CervoMed Inc CRVO

Healthcare Biotechnology
CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders. It is focused on the development of its lead drug candidate, neflamapimod, an investigational, orally administered, small molecule brain penetrant that inhibits p38a in the neurons (nerve cells) within the brains of people with neurodegenerative diseases. Its... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:CRVO)

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 12, 2024

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

GlobeNewswire December 10, 2024

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

GlobeNewswire November 27, 2024

CervoMed Announces Key Senior Leadership Appointments

GlobeNewswire November 13, 2024

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

GlobeNewswire November 12, 2024

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

GlobeNewswire November 8, 2024

CervoMed to Participate in Upcoming Investor Conferences

GlobeNewswire November 7, 2024

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

GlobeNewswire November 4, 2024

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

GlobeNewswire October 29, 2024
View More News ››

Opinion & Analysis (NDAQ:CRVO)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:CRVO)

Neutral Recommendation Issued On CRVO By H.C. Wainwright

JUST IN: $CRVO Neutral Recommendation Issued On CRVO By H.C. Wainwright2024-12-17 06:30:06 ET H.C. Wainwright analyst issues NEUTRAL...
whytestocks - 8 days ago

CervoMed Announces Orphan Drug Designation Granted to Neflam

NEWS: $CRVO CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of...
whytestocks - November 27, 2024
View more Bullboard ››

Africa Oil Corp.

Africa Oil Corp.

Africa Oil Corp. is a Canadian oil and gas company with producing and development assets in deepwater Nigeria, an interest in ...
View More »